000108317 001__ 108317
000108317 005__ 20230519145352.0
000108317 0247_ $$2doi$$a10.1016/j.pcd.2020.10.005
000108317 0248_ $$2sideral$$a121162
000108317 037__ $$aART-2021-121162
000108317 041__ $$aeng
000108317 100__ $$aLou, G.
000108317 245__ $$aEffect of CGM in the HbA1c and Coefficient of Variation of glucose in a pediatric sample
000108317 260__ $$c2021
000108317 5060_ $$aAccess copy available to the general public$$fUnrestricted
000108317 5203_ $$aAim of the study: Previous studies have found no significant improvements in glycated hemoglobin (HbA1c), while using Continuous Glucose Monitoring (CGM), with children and adolescents. The aim of this paper is to measure the change in HbA1c, and the Coefficient of Variation in glucose levels, when using CGM, once the effect of other relevant variables, such as gender, actual age, the years the patient has had diabetes, use of an insulin pump, the presence of autoimmune disease, other associated pathologies, and weekly hours of exercise, are controlled for. Methods: This is a retrospective study that uses a linear regression model. Data was collected from Type 1 Diabetes Mellitus (T1DM), children diagnosed between 2003 and 2017 in the Pediatric Unit for Diabetes in Zaragoza, Spain. We used a linear regression and the method of estimation is Ordinary Least Squares. Results: Results show that the use of CGM decreased the HbA1c value by 3.5% and the Coefficient of Variation by 14%. Conclusions: The implication of these results is that this device helped in the management of diabetes, although more research is needed to distinguish between different devices in terms of their efficacy.
000108317 540__ $$9info:eu-repo/semantics/openAccess$$aAll rights reserved$$uhttp://www.europeana.eu/rights/rr-f/
000108317 590__ $$a2.567$$b2021
000108317 591__ $$aPRIMARY HEALTH CARE$$b10 / 18 = 0.556$$c2021$$dQ3$$eT2
000108317 591__ $$aENDOCRINOLOGY & METABOLISM$$b119 / 147 = 0.81$$c2021$$dQ4$$eT3
000108317 594__ $$a3.2$$b2021
000108317 592__ $$a0.6$$b2021
000108317 593__ $$aEndocrinology, Diabetes and Metabolism$$c2021$$dQ2
000108317 593__ $$aInternal Medicine$$c2021$$dQ2
000108317 593__ $$aFamily Practice$$c2021$$dQ2
000108317 655_4 $$ainfo:eu-repo/semantics/article$$vinfo:eu-repo/semantics/acceptedVersion
000108317 700__ $$0(orcid)0000-0001-5858-4975$$aLarramona, G.$$uUniversidad de Zaragoza
000108317 700__ $$0(orcid)0000-0002-9253-6448$$aMontaner, T.$$uUniversidad de Zaragoza
000108317 700__ $$aBarbed, S.
000108317 7102_ $$14000$$2415$$aUniversidad de Zaragoza$$bDpto. Análisis Económico$$cÁrea Fund. Análisis Económico
000108317 7102_ $$14011$$2095$$aUniversidad de Zaragoza$$bDpto. Direc.Mark.Inves.Mercad.$$cÁrea Comerci.Investig.Mercados
000108317 773__ $$g15, 2 (2021), P289-292$$pPrimary care diabetes$$tPrimary care diabetes$$x1751-9918
000108317 8564_ $$s156235$$uhttps://zaguan.unizar.es/record/108317/files/texto_completo.pdf$$yPostprint
000108317 8564_ $$s2707648$$uhttps://zaguan.unizar.es/record/108317/files/texto_completo.jpg?subformat=icon$$xicon$$yPostprint
000108317 909CO $$ooai:zaguan.unizar.es:108317$$particulos$$pdriver
000108317 951__ $$a2023-05-18-13:27:30
000108317 980__ $$aARTICLE